NeuroPointDX

NeuroPointDX is a precision medicine company specializing in the development of blood-based diagnostic tests for neurodevelopmental disorders, with a primary focus on Autism Spectrum Disorder (ASD). As a division of Stemina Biomarker Discovery, the company leverages a proprietary metabolomics platform to identify specific metabolic subtypes, or metabotypes, in children with autism. Their lead product, the NPDX ASD Test, evaluates a panel of amino acids and other metabolites to provide clinicians with actionable insights for personalized nutritional or medical interventions. The company's goal is to enable earlier diagnosis and more effective, individualized treatment plans for patients on the autism spectrum. By integrating metabolic profiling with clinical data, NeuroPointDX aims to improve therapeutic outcomes for neurodevelopmental conditions.